| (USD) | Jun 2022 | Q/Q |
|---|---|---|
| Revenue | 13.1MM | +3% |
| Operating Income | -7MM | -15% |
| Operating Expenses | 20.2MM | -4% |
| Net Income | -6.8MM | -16% |
| R&D | 12.8MM | -10% |
| G&A | 7.4MM | +10% |
| Interest Expense | 649K | +8% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Codiak BioSciences Inc (NASDAQ: CDAK) voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets. The company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties. The company expects to consummate a sale of the entire business or its core assets. Codiak BioScien
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the Company has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets which is intended to maximize the value o
CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual Evercore ISI HealthCONx Conference, a virtual conference. Codiak’s Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat on Wednesday, November 30 at 8:00 am ET and the Co
– exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting cancer subtypes for treatment with exoASO-STAT6 – – Systemically administered exoASO-C/EBPβ demonstrated extra-hepatic delivery and potent systemic anti-tumor activity across multiple myeloid-derived suppressor cell (MDSC) rich tumor models – – A Phase 1 clinical trial of exoASO-STAT6 in patients with a
Codiak BioSciences ( NASDAQ:CDAK ) Third Quarter 2022 Results Key Financial Results Revenue: US$522.0k (down 55% from...
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
– Patient enrollment continuing in Phase 1 clinical trial of exoASO™-STAT6 in patients with advanced hepatocellular carcinoma; preliminary data anticipated during 1H 2023 – – Presented preclinical data showing exoVACC™ pan beta coronavirus vaccine, supported by CEPI, elicits broad protective immunity against variants of SARS-CoV-2 and other potentially human transmissible animal coronaviruses – – Two preclinical abstracts accepted at SITC 2022 for exoASO-STAT6 and exoASO™-C/EBPβ – CAMBRIDGE, Mas
Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022. The stock rises in the after-market trading.
BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.
Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.